BAAM
VYNT

Baker Avenue Asset Management’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Baker Avenue Asset Management’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-71
Closed -$120K – 313
2014
Q2 		$120K Buy
+71
New +$135K 0.02% 286

Other funds holding VYNT

Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
CM
Castleark Management Chicago, Illinois $3.02B AUM 53.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
GMCM
Gruber & McBaine Capital Management San Francisco, California $369M AUM 12.23% 1-Year Est. Return
SIM
SSI Investment Management Los Angeles, California $1.45B AUM 5.8% 1-Year Est. Return
SCM
Sterneck Capital Management Kansas City, Missouri $223M AUM 17.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Diker Management New York $112M AUM 59.78% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Baker Avenue Asset Management's VYNT Position: Q3 2014 in Review

Baker Avenue Asset Management sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q3 2014, closing a stake of 71 shares — an estimated $120K sold.

Baker Avenue Asset Management first reported a position in VYNT in Q2 2014 and held it in 1 quarter. The position peaked at $120K in Q2 2014. 28 funds tracked by Wall St. Rank hold VYNT as of Q3 2014.

  • Baker Avenue Asset Management reported no remaining Vyant Bio, Inc. Common Stock position as of Q3 2014 after selling out during the quarter.
  • Baker Avenue Asset Management sold 71 Vyant Bio, Inc. Common Stock shares in Q3 2014, an estimated $120K.
  • Baker Avenue Asset Management first reported a position in Vyant Bio, Inc. Common Stock in Q2 2014 and held it in 1 quarter.
  • Baker Avenue Asset Management's Vyant Bio, Inc. Common Stock position peaked at $120K in Q2 2014.
  • 28 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q3 2014.

Based on Baker Avenue Asset Management's 13F filing for Q3 2014, filed 12 Nov 2014.